BioBlast Pharma: an under the radar ultra-rare disease company

  Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three diversified platforms currently address five different diseases. The platforms include Cabaletta, which is a platform for diseases characterized by mutated proteins; BBrm platform is a […]

TRIL – Preparing For The Next Move Upward

  Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat” signal to macrophages. High expression of CD47 by tumor cells has been correlated with more aggressive disease and poor survival. SIRPαFc is initially being developed […]

Quick update from TRIL Presentation in Toronto

  Trillium Therapeutics Inc. (TRIL) – Nasdaq   Trillium Therapeutics presented at Bloomburton-2015 Healthcare Investor Conference in Toronto on May 5th, the speaker Dr. Rob Uger, TRIL’s Chief Scientific Officer (CSO) was very informative during the presentation, mentioned that TRIL are looking for a combination therapy with other immunological agents such as Approved cancer antibodies, T cell […]

SRPT- A Squeeze In The Making

  Sarepta Therapeutics, Inc. (SRPT)-Nasdaq   Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan Stanley Healthcare Conference on September 10th. We received guidance in April from the FDA that outlined a very clear path-forward, which resulted in a plan […]

SPY – A Quick Look at The Broader Market

SPDR S&P 500 (SPY) –NYSE   Yesterday we got a sharp turn in the SP-500 as the daily chart of the SPY (S&P 500 ETF) drops sharply and breaks down the uptrend channel for the first time after two months of uptrend within the channel. Breaking down the 50-Day moving average as well which was supposed be […]

Tekmira – Is It The Bottom Yet

  Tekmira Pharmaceuticals Corp (TKMR) –Nasdaq   Tekmira is the new “fallen star” after the wild run started Jan 07th, 2014 from $7.66, and reaching the all time high $31.48 mid March. But that was the inflection point as well, the price start dropping fast with no stops or even real technical correction, reaching the support […]

BMY – In The Inflection Point

  Bristol-Myers Squibb Company (BMY) –NYSE   Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $41.11 in late August 2013 to reach a new 12 years high $57.49 in early March 2014, as investors were anticipating the anti PD-1 data coming at ASCO-2014 and with high expectations for  BMY’s data of […]

RTRX – In a Consolidation Mode

Retrophin, Inc. (RTRX) –Nasdaq   During the last 13 trading days, RTRX trading along the 200-Day moving avarage (red line) with small candlestick (doji) on a descending volume confirming the consolidation mode. The MACD moving to the positive territory along with the RSI positive momentum as well. the next resistance line is the 50-Day moving average […]